It could actually be cheaper than other treatment options.
The U.S. Food and Drug Administration (FDA) recently approved a new drug Hemgenix, to be used in patients with hemophilia B, a blood clotting disorder. Since the condition is rare, it will be used only in a small group of patients worldwide.
Motortion/iStock.
Since Hemophilia patients lack enough clotting factor, so they are at risk of complications of prolonged bleeding that can also affect joints, internal organs, and the brain, an FDA document said. Treatment for such individuals constitutes intravenous infusions of clotting Factor IX to prevent bleeding episodes, which must be conducted over the patient’s lifetime.
Comments are closed.